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Abstract
IMPORTANCE—The prevalence of cardiometabolic multimorbidity is increasing.
OBJECTIVE—To estimate reductions in life expectancy associated with cardiometabolic 
multimorbidity.
DESIGN, SETTING, AND PARTICIPANTS—Age- and sex-adjusted mortality rates and 
hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk 
Factors Collaboration (689 300 participants; 91 cohorts; years of baseline surveys: 1960–2007; 
latest mortality follow-up: April 2013; 128 843 deaths). The HRs from the Emerging Risk Factors 
Collaboration were compared with those from the UK Biobank (499 808 participants; years of 
baseline surveys: 2006–2010; latest mortality follow-up: November 2013; 7995 deaths). 
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Cumulative survival was estimated by applying calculated age-specific HRs for mortality to 
contemporary US age-specific death rates.
EXPOSURES—A history of 2 or more of the following: diabetes mellitus, stroke, myocardial 
infarction (MI).
MAIN OUTCOMES AND MEASURES—All-cause mortality and estimated reductions in life 
expectancy.
RESULTS—In participants in the Emerging Risk Factors Collaboration without a history of 
diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the 
age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in 
participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in 
those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with 
both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference 
group, the HRs for all-cause mortality were 1.9 (95%CI, 1.8–2.0) in participants with a history of 
diabetes, 2.1 (95%CI, 2.0–2.2) in those with stroke, 2.0 (95%CI, 1.9–2.2) in those with MI, 3.7 
(95%CI, 3.3–4.1) in those with both diabetes and MI, 3.8 (95%CI, 3.5–4.2) in those with both 
diabetes and stroke, 3.5 (95%CI, 3.1–4.0) in those with both stroke and MI, and 6.9 (95%CI, 5.7–
8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors 
Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were 
little changed after further adjustment for markers of established intermediate pathways (eg, levels 
of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a 
history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a 
history of all 3 of these conditions was associated with 15 years of reduced life expectancy.
CONCLUSIONS AND RELEVANCE—Mortality associated with a history of diabetes, stroke, 
or MI was similar for each condition. Because any combination of these conditions was associated 
with multiplicative mortality risk, life expectancy was substantially lower in people with 
multimorbidity.
The prevalence of cardiometabolic multimorbidity (defined herein as a history of ≥2 of the 
following: diabetes mellitus, stroke, myocardial infarction [MI]) is increasing rapidly.1–3 
Considerable evidence exists about the mortality risk of having any 1 of these conditions 
alone.4–7 However, evidence is sparse about life expectancy among people who have 2 or 3 
cardiometabolic conditions concomitantly. Valid estimation of the associations of 
cardiometabolic multimorbidity with mortality requires comparison of people with 
multimorbidity with participants within the same cohorts who did not have any of the 
conditions at baseline. However, few population cohorts have had sufficient power, detail, 
and longevity to enable such comparisons.8–14
We aimed to provide reliable estimates of the associations of cardiometabolic 
multimorbidity with mortality and reductions in life expectancy. We analyzed individual 
participant data in the Emerging Risk Factors Collaboration (ERFC) from 689 300 
participants recruited during 1960 through 2007 into 91 prospective cohorts that have 
recorded mortality during prolonged follow-up. We compared the ERFC results with those 
from the UK Biobank, a prospective cohort study of 499 808 participants recruited during 
2006 through 2010.
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Our analysis involved several interrelated components (eFigure 1 in the Supplement). First, 
we quantified associations of cardiometabolic multimorbidity with all-cause mortality. To 
maximize power, we analyzed data from the ERFC in which a total of about 129 000 deaths 
have accrued. Second, we compared results from the ERFC with those from the UK 
Biobank. The UK Biobank recruited participants more recently than the ERFC and it had 
accrued about 8000 deaths at the time of this analysis. Third, we estimated reductions in life 
expectancy associated with cardiometabolic multimorbidity by applying results from the 
ERFC to contemporary US age-specific death rates. Fourth, we placed our findings in the 
context of previous relevant studies identified through a systematic review.
Data Sources
Both the ERFC and the UK Biobank have been described.15–17 Prospective cohort studies 
contributing to the ERFC were included in this analysis if they met all the following criteria: 
(1) had recruited participants on the basis of informed consent, (2) had recorded information 
about the diagnosis of diabetes, stroke, and MI at the baseline survey, (3) did not select 
participants on the basis of having previous chronic disease (including cardiovascular 
disease and diabetes), (4) had recorded cause-specific deaths, and (5) had accrued more than 
1 year of follow-up. Details of the contributing studies in the ERFC are presented in eTable 
1 and eAppendix 2 in the Supplement. Information on the methods used to characterize 
diagnosis of diabetes, stroke, and MI at the baseline survey are presented in eTable 2. The 
contributing studies classified deaths according to the primary cause (or, in its absence, the 
underlying cause), on the basis of coding from the International Classification of Diseases, 
Eighth-Tenth Revisions, to at least 3 digits, or according to study-specific classification 
systems. Classification of deaths was based on death certificates, which was supplemented 
in 53 studies by medical records, findings on autopsy, and other sources. The date of the 
latest mortality follow-up was April 2013.
In the UK Biobank, information on a baseline history of diabetes, stroke, and MI was 
available for 499 808 participants recruited from 22 centers throughout the United Kingdom 
(eAppendix 3 in the Supplement). After giving consent, participants provided biological 
samples and completed a touch-screen questionnaire, a computer-assisted interview, and a 
physical examination. Participants have been linked with the death records of the UK Office 
for National Statistics through National Health Service identification numbers. Deaths were 
classified according to the primary cause (or, in its absence, the underlying cause), or on the 
basis of coding from the International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision, to at least 3 digits. The date of the latest mortality follow-
up was November 2013.
Details of our systematic review of population-based prospective studies reported between 
January 1970 and April 2015 appear in eAppendix 4 in the Supplement. No language 
restrictions were applied to the publications. Studies were not eligible for the review if they 
had contributed data to the ERFC.8,13,18 Two authors (P.W. and L.M.O.K.) extracted and 
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cross-checked information from publications according to a prespecified protocol and 
disagreements were resolved by a third author (E.D.A.).
Approval was provided by the Cambridgeshire Ethics Review Committee.
Statistical Analysis
For both the ERFC and the UK Biobank, we categorized participants into the following 8 
mutually exclusive groups according to baseline disease: (1) diabetes, (2) stroke, (3) MI, (4) 
diabetes and MI, (5) diabetes and stroke, (6) stroke and MI, (7) diabetes, stroke, and MI, (8) 
none of these (reference group). We assessed associations of these baseline groups with the 
risk of death from any cause.
Hazard ratios (HRs) were calculated using Cox proportional hazards regression models. The 
principal objective of our study was to estimate reductions in life expectancy associated with 
having different combinations of cardiometabolic multimorbidity. To this end, our primary 
analysis calculated HRs stratified by sex and adjusted for age only. A secondary objective 
was to explore the extent to which markers of some established intermediate pathways (ie, 
total and high-density lipoprotein cholesterol, blood pressure, body mass index) and lifestyle 
factors (ie, smoking, diet, socioeconomic status) could explain associations between 
cardiometabolic multimorbidity and mortality. To this end, subsidiary analyses calculated 
HRs adjusted for these additional factors. The HRs in the ERFC were calculated using a 2-
stage approach, with estimates calculated separately within each study before pooling across 
studies by random-effects meta-analysis using an extension of the DerSimonian and Laird 
procedure.16,19
Participants were included in the analyses irrespective of previous nonfatal events. For each 
specific cause of death, outcomes were censored if a participant was lost to follow-up, died 
of other causes, or reached the end of the follow-up period. The proportional hazards 
assumption was satisfied for all-cause mortality (eFigure 2 in the Supplement). We used the 
I2 statistic to quantify between-study heterogeneity and the Wald test to assess interactions.
Because age-specific mortality rates cannot be directly obtained from a 2-stage approach 
using Cox regression models (ie, these models estimate instantaneous probability of death), 
we used a 2-level mixed-effects Poisson regression model with random study intercept 
adjusted for baseline disease status, sex and age at risk (linear and quadratic terms), and 
interactions of age at risk with the preceding variables. This Poisson regression model was 
used to obtain mortality rates adjusted to the age of 60 years (ie, marginal effects).
Detail of the methods used to estimate reductions in life expectancy is in eAppendix 5 in the 
Supplement. Briefly, estimates of cumulative survival from 40 years of age onward among 
the 8 baseline disease groups were calculated by applying the HRs for cause-specific 
mortality from the ERFC (specific to age at risk and sex) to the detailed mortality 
component of the US Centers for Disease Control and Prevention’s CDC WONDER 
database, which recorded almost 10 million deaths among more than 305 million individuals 
during 2007 through 2010.20,21 We modeled results throughout middle age and old age, 
giving specific consideration to the HRs with cardiometabolic multimorbidity recorded by 
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the age of 60 years, the period of life when multimorbidity becomes increasingly common.22 
Analyses involved Stata version 12.0 (StataCorp), 2-sided P values, and used a significance 
level of P < .05.
Results
Emerging Risk Factors Collaboration
At baseline, the mean (SD) age was 53 (9) years and 51% were women (Table 1). The large 
majority of participants were enrolled in Europe (69%) or North America (24%) (eTable 1 
in the Supplement). Of 689 300 participants, 24 677 (3.6%) had a history of diabetes at 
enrollment, 8583 (1.2%) had stroke, 21 591 (3.1%) had MI, 3233 (0.5%) had a history of 
both diabetes and MI, 1321 (0.2%) had both diabetes and stroke, 1836 (0.3%) had both 
stroke and MI, and 541 (0.1%) had diabetes, stroke, and MI. There were 128 843 deaths (50 
595 due to vascular causes; 39 266, cancer; 30 664, other causes; and 8318, unknown or ill-
defined causes) during8.83 million person-years at risk (median follow-up, 12.8 years; 5th–
95th percentile, 4.0–29.5 years) (eTable 1).
In the reference group, the sex-adjusted mortality rate at the age of 60 years was 6.8 (95% 
CI, 6.2–7.4) per 1000 person-years at risk. By contrast, the age- and sex-adjusted mortality 
rates were 15.6 (95% CI, 14.1–17.0) in participants with a history of diabetes, 16.1 (95% CI, 
14.4–17.8) in those with stroke, 16.8 (95% CI, 15.2–18.3) in those with MI, 32.0 (95% CI, 
28.1–35.9) in those with a history of both diabetes and MI, 32.5 (95% CI, 27.0–37.9) in 
those with both diabetes and stroke, 32.8 (95% CI, 28.1–37.6) in those with both stroke and 
MI, and 59.5 (95% CI, 47.0–71.9) in those with diabetes, stroke, and MI (Figure 1).
Compared with the reference group, the age- and sex-adjusted HRs for mortality were 1.9 
(95% CI, 1.8–2.0) for participants with a history of diabetes, 2.1 (95% CI, 2.0–2.2) in those 
with stroke, 2.0 (95% CI, 1.9–2.2) in those with MI, 3.7 (95% CI, 3.3–4.1) in those with a 
history of both diabetes and MI, 3.8 (95% CI, 3.5–4.2) in those with both diabetes and 
stroke, 3.5 (95% CI, 3.1–4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7–8.3) in 
those with diabetes, stroke, and MI (Figure 1).
The HRs for participants with a history of 2 or more conditions were generally consistent 
with multiplicative effects (P > .05 for deviation from multiplicative effects), with the 
exception of the HR for those with a history of both stroke and MI (P < .001). The HRs were 
stronger among women than men for participants with diabetes only, stroke only, and those 
with both diabetes and MI (P < .001; eFigure 3 in the Supplement). The HRs were little 
changed after additional adjustment for smoking (Table 2). The HRs attenuated slightly after 
further adjustment for total and high-density lipoprotein cholesterol, systolic blood pressure, 
and body mass index. In participants with all 3 conditions at baseline, the age- and sex-
adjusted HRs were 11.8 (95% CI, 9.6–14.6) for cardiovascular mortality, 2.1 (95%CI, 1.5–
2.9) for cancer mortality, and 7.9(95% CI, 6.6–9.6) for the aggregate of nonvascular, 
noncancer deaths (eFigure 4).
Broadly similar HRs to those noted above were observed in analyses that (1) used 
alternative definitions of baseline disease (eFigure 5 in the Supplement), (2)were restricted 
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to studies that supplemented death certificates with additional information (eFigure 6), (3) 
excluded the initial 5 years of follow-up (eFigure 7), or (4) used fixed-effect meta-analysis 
(eFigure 8). The HRs for mortality appeared to decline somewhat with increasing calendar 
year of baseline study enrollment (eFigure 9).
UK Biobank
At baseline, the mean (SD) age was 57 (8) years and 55%were women (Table 1). Of 499 
808 participants, 18 549 (3.7%) had a history of diabetes at enrollment,6835 
(1.4%)hadstroke,8770 (1.8%) had MI, 2036 (0.4%) had a history of both diabetes and MI, 
966 (0.2%) had both diabetes and stroke, 688 (0.1%) had both stroke and MI, and 230 
(0.05%) had diabetes, stroke, and MI. There were 7995 deaths during 2.39 million person-
years at risk (median follow-up, 4.8 years; interquartile range, 4.1–5.5 years).
Compared with the reference group, the age- and sex-adjusted HRs for mortality were 1.6 
(95% CI, 1.5–1.8) for participants with diabetes, 2.1 (95% CI, 1.9–2.4) for those with stroke, 
2.1 (95% CI, 1.9–2.3) for those with MI, 4.3 (95% CI, 3.7–5.0) for those with both diabetes 
and MI, 3.9 (95% CI, 3.1–4.9) for those with both diabetes and stroke, 3.8 (95% CI, 2.9–4.9) 
for those with both stroke and MI, and 6.0 (95% CI, 4.2–8.7) for those with diabetes, stroke, 
and MI (Figure 2 and eTable 3 in the Supplement). The HRs were little changed after 
additional adjustment for smoking, systolic blood pressure, body mass index, diet, and 
socioeconomic status (Table 2).
Estimated Reductions in Life Expectancy
We estimated that at the age of 60 years, men with any 2 of the cardiometabolic conditions 
we studied would on average have 12 years of reduced life expectancy, and men with all 3 
conditions would have 14 years of reduced life expectancy (Figure 3 and eTable 4 in the 
Supplement). For women at the age of 60 years, the corresponding estimates were 13 years 
and 16 years of life lost. When calculated for patients at younger ages, estimated reductions 
in life expectancy were greater than for older patients (eg, 23 years of life were estimated to 
be lost for men at age 40 years with 3 conditions compared with 20 years of life lost for men 
at age 50 years with 3 conditions). Estimated reductions in life expectancy in patients with 
MI only were greater for men than women; estimated reductions in life expectancy in 
patients with diabetes only were greater for women (Figure 3 and eTable 4).
On average, about 59% of the survival difference associated with cardiometabolic 
multimorbidity in men was attributed to excess cardiovascular deaths, and the remainder to 
excess nonvascular, noncancer deaths (36%), cancer deaths (4%), and unclassified deaths 
(1%). By contrast, for women, 45% of the estimated survival difference was attributed to 
excess cardiovascular deaths, and the remainder by nonvascular, noncancer deaths (49%), 
excess cancer deaths (5%), and unclassified deaths (2%) (eFigure 10 in the Supplement). 
Broadly similar results were observed when modeling involved cause-specific death rates 
from the European Union (eFigure 11).
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We could not identify any previous relevant reports of all-cause mortality that had 
investigated participants having the combination of diabetes, stroke, and MI, or any previous 
relevant reports of participants having the combination of stroke and MI. We identified only 
1 previous relevant report on the combination of diabetes and stroke, albeit of limited 
statistical power.23 By contrast, we identified 5 previous reports on the combination of 
diabetes and MI, which generally yielded similar HRs as in the current analysis (Figure 2 
and eTable 5 in the Supplement), although none estimated reductions in life expectancy 
associated with such multimorbidity.9–12,14
Discussion
Our analysis of more than 135 000 deaths accrued during prolonged follow-up of almost 1.2 
million participants in population cohorts has provided estimates of reductions in life 
expectancy associated with different combinations of cardiometabolic multimorbidity (ie, a 
history of diabetes, stroke, and/or MI). Each of our 3 main findings has potential 
implications.
First, in patients who had only 1 condition that we studied, we observed an HR for mortality 
of about 2; for a combination of any 2 conditions, the HR was about 4; and for a 
combination of all 3 conditions, the HR was about 8. These results suggest that associations 
of cardiovascular disease and diabetes with mortality are multiplicative and essentially 
nonoverlapping. This finding is consistent with previous observations that associations of 
diabetes with chronic disease outcomes are largely independent of major cardiovascular risk 
factors.5,24 Consequently, our results emphasize the importance of measures to prevent 
cardiovascular disease in people who already have diabetes, and, conversely, to avert 
diabetes in people who already have cardiovascular disease.25,26
Second, our results suggest that estimated reductions in life expectancy associated with 
cardiometabolic multimorbidity are of similar magnitude to those previously noted for 
exposures of major concern to public health, such as lifelong smoking (10 years of reduced 
life expectancy27) and infection with the human immunodeficiency virus (11 years of 
reduced life expectancy28,29). For example, cardiometabolic multimorbidity at the age of 60 
years was associated with an average reduction in life expectancy of about 15 years. We 
estimated even greater reductions in life expectancy in patients with multimorbidity at 
younger ages, such as 23 years of life lost in patients with 3 conditions at the age of 40 
years.
Third, we noted modification by sex of associations between cardiometabolic 
multimorbidity and mortality. For men, the association between baseline cardiovascular 
disease (ie, a history of stroke or MI) and reduced survival was stronger than for women, 
whereas the association between baseline diabetes and reduced survival was stronger for 
women. Consequently, about 60% of the years of life lost from cardiometabolic 
multimorbidity can be attributed to cardiovascular deaths for men compared with only about 
45% for women. Nevertheless, for both men and women, our findings indicate that 
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associations of cardiometabolic multimorbidity extend beyond cardiovascular mortality. 
Future work will seek to elucidate explanations for these interactions by sex.
Our results highlight the need to balance the primary prevention and secondary prevention 
of cardiovascular disease. About 1% of the participants in the cohorts we studied had 
cardiometabolic multimorbidity compared with an estimate of 3% from recent surveys in the 
United States.30,31 There are currently an estimated 10 million adults in the United States 
and the European Union with cardiometabolic multimorbidity.1,3,20,21 Nevertheless, an 
overemphasis on the substantial reductions in life expectancy estimated for the 
subpopulation with multimorbidity could divert attention and resources away from 
population-wide strategies that aim to improve health for the large majority of the 
population.32
Our study had potential limitations. Our definition of cardiometabolic multimorbidity was 
both pragmatically motivated (we had information available on a history of diabetes, stroke, 
and MI) and biologically motivated (we purposefully focused on binary disease states). 
However, we did not include a history of hypertension in our definition of multimorbidity 
because categorizing elevated blood pressure as a binary variable would necessarily 
underestimate the true effect of blood pressure on chronic disease because blood pressure 
has a continuous log-linear relationship with the risk of cardiovascular diseases throughout 
its range of values.33 Furthermore, inclusion of hypertension in our definition would have 
created 16 possible disease combinations, which are too many for stable analyses even in the 
ERFC. We did not have access to time-varying exposure information to enable updating of 
multimorbidity status during follow-up. Only subsets of participants had information on 
some covariates, such as medication use, and dates of diagnosis of baseline conditions.
The generalizability of our results was enhanced by involvement in the ERFC of individual 
participant data from 91 cohorts in 18 different countries that recruited participants during 
1960 through 2007. To what extent do the HRs from the ERFC reflect the contemporary 
situation? Our study addressed this concern in several ways. We analyzed data in the ERFC 
by calendar decade, and we did not find evidence of large differences in the HRs by calendar 
period of recruitment. We noted broadly similar findings between the ERFC and the UK 
Biobank, which recruited participants during 2006 through 2010. Our systematic review 
found that the HRs reported in previous relevant publications were compatible with those in 
the ERFC, although previous data were sparse. In addition, for the survival modeling, we 
applied the HRs observed in the ERFC to the death rates derived from the contemporary US 
population and secondarily to the European Union population.
Conclusions
Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. 
Because any combination of these conditions was associated with multiplicative mortality 
risk, life expectancy was substantially lower in people with multimorbidity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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All-Cause Mortality for the Emerging Risk Factors Collaboration by Disease Status of 
Participants at Baseline
The mortality rates were calculated using a Poisson regression model and are sex-adjusted 
rates to the age of 60 years. The hazard ratios were calculated using a Cox proportional 
hazards regression model and are stratified by sex and adjusted by age at baseline. Analyses 
were based on participants from 91 studies.
MI indicates myocardial infarction.
a
 Mortality rate is per 1000 person-years.
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All-Cause Mortality From the Emerging Risk Factors Collaboration Compared With the UK 
Biobank and Previous Reports
The hazard ratios were adjusted for sex when appropriate and age, except those for the 
Hispanic Established Population for the Epidemiological Study of the Elderly, which were 
adjusted for additional variables. MI indicates myocardial infarction. The size of the data 
markers is proportional to the information content in each study.
a
 For participant-level analyses in the Emerging Risk Factors Collaboration and the UK 
Biobank, participants with the disease status indicated at baseline have been compared with 
participants within the same cohorts without diabetes, stroke, or myocardial infarction at 
baseline.
b
 For previously published studies, participants with cardiometabolic multimorbidity at 
baseline were compared with participants without any such conditions.
c
 Used history of coronary heart disease instead of history of MI.
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Modeling of Years of Life Lost by Disease Status of Participants at Baseline Compared 
With Those Free of Diabetes, Stroke, and Myocardial Infarction (MI)
The estimates of cumulative survival from 40 years of age onward among the 8 baseline 
disease groups were calculated by applying hazard ratios (specific to age at risk and sex) for 
all-cause mortality associated with baseline disease status to US cause-specific death rates at 
the age of 40 years or older.
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